Privately-held Ventus Therapeutics, a biopharma with two novel small-molecule programs entering Phase II development for ...

Biogen receives exclusive rights to commercialize zorevunersen outside U.S., Europe, and Japan.

Merck’s Keytruda may be the most talked about drug facing loss of exclusivity but it’s far from the only one, as several of ...

Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.

Stoke Therapeutics’ stock climbed 8% early Tuesday, after the company and Biogen today announced a collaboration to develop ...

Biogen and Stoke Therapeutics have signed a deal to co-develop and sell Stoke’s experimental drug for Dravet syndrome, ...

Stoke Therapeutics Inc. and Biogen Inc. said Tuesday they are entering a collaboration to develop and commercialize a ...

BioArctic signed the first deal for its “brain transporter” with Bristol Myers Squibb late last year. The deal is worth up to $1.4bn and allows the US drugmaker to start trials using the technology to ...

Biogen’s disappointing Leqembi performance and weak pipeline hurt future growth. Learn why BIIB stock is rated "sell" due to ...

It’s critical to understand what a digitally savvy HCP is in 2025 and what’s impeding pharma's communications with this ...

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.